Protara Therapeutics, Inc. (TARA)

Market Cap	34.87M
Revenue (ttm)	n/a
Net Income (ttm)	-40.42M
Shares Out	11.43M
EPS (ttm)	-3.57
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	262,558
Open	2.800
Previous Close	2.820
Day's Range	2.750 - 3.050
52-Week Range	1.040 - 5.240
Beta	1.88
Analysts	Strong Buy
Price Target	25.00 (+719.67%)
Earnings Date	May 6, 2024

About TARA

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutritio...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Jesse Shefferman
• Employees: 26
• Stock Exchange: NASDAQ
• Ticker Symbol: TARA

Analyst Forecast

According to 3 analysts, the average rating for TARA stock is "Strong Buy." The 12-month stock price forecast is $25.0, which is an increase of 719.67% from the latest price.

Price Target

$25.0

(719.67% upside)

Analyst Consensus: Strong Buy